The availability of sufficient quantities of recombinant human cytokines and promising preclinical data have led to their introduction into clinical trials. Cytokines have potential as new therapeutic agents in a variety of hematological disorders as well as in solid tumors. Only a few of the still increasing number of these glycoprotein hormones have been studied in humans so far, either as single agents or in combination with chemotherapy and other cytokines. Their clinical effects, beneficial role in supportive care, and use in the treatment of certain cancer patients are reviewed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/stem.5530090403 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!